Progressive Multifocal Leukoencephalopathy - Pipeline Review, H1 2018

  • ID: 4537880
  • Report
  • 28 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Neurimmune Holding AG
  • Neuway Pharma GmbH
  • Pomona Ricerca SRL
  • MORE
Progressive Multifocal Leukoencephalopathy - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Progressive Multifocal Leukoencephalopathy - Pipeline Review, H1 2018, provides an overview of the Progressive Multifocal Leukoencephalopathy (Infectious Disease) pipeline landscape.

Progressive multifocal leukoencephalopathy (PML) is a demyelinating disease of the brain caused by lytic infection of oligodendrocytes by the JC polyomavirus. Symptoms include clumsiness, progressive weakness, and visual, speech, and sometimes personality changes. Risk factors include the presence of pathogenic JCV and an altered or weakened immune system, genetic or environmental factors.

Report Highlights:

This latest pipeline guide Progressive Multifocal Leukoencephalopathy - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Progressive Multifocal Leukoencephalopathy (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Progressive Multifocal Leukoencephalopathy (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Progressive Multifocal Leukoencephalopathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Preclinical and Discovery stages are 4 and 3 respectively.

Progressive Multifocal Leukoencephalopathy (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Progressive Multifocal Leukoencephalopathy (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Progressive Multifocal Leukoencephalopathy (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Progressive Multifocal Leukoencephalopathy (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Progressive Multifocal Leukoencephalopathy (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Progressive Multifocal Leukoencephalopathy (Infectious Disease)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Progressive Multifocal Leukoencephalopathy (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Progressive Multifocal Leukoencephalopathy (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Neurimmune Holding AG
  • Neuway Pharma GmbH
  • Pomona Ricerca SRL
  • MORE
Introduction

Report Coverage

Progressive Multifocal Leukoencephalopathy - Overview

Progressive Multifocal Leukoencephalopathy - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Progressive Multifocal Leukoencephalopathy - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Molecule Type

Progressive Multifocal Leukoencephalopathy - Companies Involved in Therapeutics Development

Excision BioTherapeutics Inc

Neurimmune Holding AG

Neuway Pharma GmbH

Pomona Ricerca SRL

Progressive Multifocal Leukoencephalopathy - Drug Profiles

EBT-103 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IkT-01427 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody for JCV and PML Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NI-307 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NPW-007 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PNJC-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Activate Sirtuin for Viral Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Progressive Multifocal Leukoencephalopathy - Dormant Projects

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Progressive Multifocal Leukoencephalopathy, H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Progressive Multifocal Leukoencephalopathy - Pipeline by Excision BioTherapeutics Inc, H1 2018

Progressive Multifocal Leukoencephalopathy - Pipeline by Neurimmune Holding AG, H1 2018

Progressive Multifocal Leukoencephalopathy - Pipeline by Neuway Pharma GmbH, H1 2018

Progressive Multifocal Leukoencephalopathy - Pipeline by Pomona Ricerca SRL, H1 2018

Progressive Multifocal Leukoencephalopathy - Dormant Projects, H1 2018

List of Figures

Number of Products under Development for Progressive Multifocal Leukoencephalopathy, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by Targets, H1 2018

Number of Products by Stage and Targets, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Excision BioTherapeutics Inc
  • Neurimmune Holding AG
  • Neuway Pharma GmbH
  • Pomona Ricerca SRL
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll